Digy

 

LIT AP Tablets

LIT AP Tablets

Composition

Each tablet contains:
Levocetirizine hydrochloride ……………5 mg
Phenylephrine hydrochloride ……………5 mg
Ambroxol  ……………………………60mg
Paracetamol …………………………350mg

Indications

LIT AP  Tablets are indicated for the relief of the symptoms of allergic rhinitis such as sneezing, rhinorrhoea, nasal congestion, itching and lacrimation. It should be administered when the antihistamine properties of levocetirizine and the nasal decongestant activity of phenylephrine are desired along with mucolytic activity of Ambroxal  and malaise .

Dosage and Administration

Adults and Adolescents (12 years and above)

One tablet twice daily.

The recommended dosage should not be exceeded.

Contraindications

Levocetirizine Hydrochloride  Hypersensitivity to levocetirizine, cetirizine or its parent compound hydroxyzine. Patients with severe renal impairment (<10 ml/min creatinine clearance) should not be administered LIT AP  Tablets. Phenylephrine Hydrochloride The product is contraindicated in patients who have previously shown intolerance to phenyleprine. Due to its phenylephrine component, LIT AP  Tablets are contraindicated in patients receiving concurrent administration of monoamine oxidase inhibitors and tricyclic antidepressants. LIT AP  Tablets are also contraindicated in patients with hypertension, aortic aneurysm, severe or unstable ischaemic heart disease, such as angina and recent myocardial infarction, and hyperthyroidism. Because phenylephrine has actions that promote smooth muscle contractility, including in the uterus, and may induce umbilical vasospasm, it should be avoided in pregnancy. There are no absolute contraindications for Amboroxal but in patients with gastric ulceration relative caution should be observed.

Packaging Information

LIT AP Tablets ……………Pack of 10 tablets